Phage Display Screening for Tumor Necrosis Factor-α-Binding Peptides: Detection of Inflammation in a Mouse Model of Hepatitis

TNF-α is one of the most abundant cytokines produced in many inflammatory and autoimmune conditions such as multiple sclerosis, chronic hepatitis C, or neurodegenerative diseases. These pathologies remain difficult to diagnose and consequently difficult to treat. The aim of this work is to offer a new diagnostic tool by seeking new molecular probes for medical imaging. The target-specific part of the probe consists here of heptameric peptides selected by the phage display technology for their affinity for TNF-α. Several affinity tests allowed isolating 2 peptides that showed the best binding capacity to TNF-α. Finally, the best peptide was synthesized in both linear and cyclic forms and tested on the histological sections of concanavalin-A-(ConA-)treated mice liver. In this well-known hepatitis mouse model, the best results were obtained with the cyclic form of peptide 2, which allowed for the staining of inflamed areas in the liver. The cyclic form of peptide 2 (2C) was, thus, covalently linked to iron oxide nanoparticles (magnetic resonance imaging (MRI) contrast agent) and tested in the ConA-induced hepatitis mouse model. The vectorized nanoparticles allowed for the detection of inflammation as well as of the free peptide. These ex vivo results suggest that phage display-selected peptides can direct imaging contrast agents to inflammatory areas.

[1]  A. Chopra.  99mTc-Labeled murine IgM monoclonal antibody, fanolesomab, that targets the CD15 glycoprotein antigen , 2011 .

[2]  Robert N. Muller,et al.  Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library , 2011, Peptides.

[3]  M. Bachmann,et al.  Averting inflammation by targeting the cytokine environment , 2010, Nature Reviews Drug Discovery.

[4]  S. Laurent,et al.  Ultrasmall particle of iron oxide--RGD peptidomimetic conjugate: synthesis and characterisation. , 2010, Bioorganic & medicinal chemistry letters.

[5]  E. Lancelot,et al.  Peptidic targeting of phosphatidylserine for the MRI detection of apoptosis in atherosclerotic plaques. , 2009, Molecular pharmaceutics.

[6]  S. Laurent,et al.  In Vivo Detection of Inflammation Using Pegylated Iron Oxide Particles Targeted at E-Selectin: A Multimodal Approach Using MR Imaging and EPR Spectroscopy , 2009, Investigative radiology.

[7]  E. Bell.  Inflammation: Targeting TNF , 2009, Nature reviews. Immunology.

[8]  W. Oyen,et al.  Development of Infection and Inflammation Targeting Compounds , 2008 .

[9]  H. Knobler,et al.  TNF-α, chronic hepatitis C and diabetes: a novel triad , 2005 .

[10]  P. Mcgeer,et al.  Inflammation and the Degenerative Diseases of Aging , 2004, Annals of the New York Academy of Sciences.

[11]  Jason E Gestwicki,et al.  Influencing receptor-ligand binding mechanisms with multivalent ligand architecture. , 2002, Journal of the American Chemical Society.

[12]  Johan Kuiper,et al.  Specific inhibition of P-selectin-mediated cell adhesion by phage display-derived peptide antagonists. , 2002, Blood.

[13]  Robert N. Muller,et al.  Theory of proton relaxation induced by superparamagnetic particles , 1999 .

[14]  C. Partidos,et al.  A peptidomimetic antagonist of TNF-alpha-mediated cytotoxicity identified from a phage-displayed random peptide library. , 1998, Journal of immunology.

[15]  George M Whitesides,et al.  Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. , 1998, Angewandte Chemie.

[16]  M. Manns,et al.  Concanavalin A-induced liver injury triggers hepatocyte proliferation. , 1998, The Journal of clinical investigation.

[17]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[18]  J. Prieto,et al.  Tumor necrosis factor α gene expression and the response to interferon in chronic hepatitis C , 1996, Hepatology.

[19]  R. Cass,et al.  Screening of cyclic peptide phage libraries identifies ligands that bind streptavidin with high affinities. , 1995, Biochemistry.

[20]  A. Wendel,et al.  A T cell-dependent experimental liver injury in mice inducible by concanavalin A. , 1992, The Journal of clinical investigation.

[21]  W. Fiers.  Precursor structures and structure-function analysis of TNF and lymphotoxin. , 1992, Immunology series.

[22]  P. Vassalli,et al.  The pathophysiology of tumor necrosis factors. , 1992, Annual review of immunology.

[23]  J. Vilček,et al.  Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. , 1991, The Journal of biological chemistry.

[24]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[25]  B. Aggarwal,et al.  Human lymphotoxin. Production by a lymphoblastoid cell line, purification, and initial characterization. , 1984, The Journal of biological chemistry.

[26]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[27]  K. Kobayashi,et al.  Studies of immune functions of patients with chronic hepatitis. , 1982, The Tohoku journal of experimental medicine.

[28]  E. Pick,et al.  The biological activities of soluble lymphocyte products. , 1972, Clinical and experimental immunology.

[29]  J. Brostoff,et al.  Interaction between "sensitized lymphocytes" and antigen in vitro. II. Mitogen-induced release of skin reactive and macrophage migration inhibitory factors. , 1970, Cellular immunology.

[30]  J. Brostoff,et al.  Interaction between "sensitized lymphocytes" and antigen in vitro. II. Mitogen-induced release of skin reactive and macrophage migration inhibitory factors. , 1970, Cellular immunology.